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The cyclins are a family of nuclear proteins that play an important
role in the control of the cell cycle. The cyclin D1 gene is located
on chromosome 11q13. It is amplified in approximately 15–20%
of breast carcinomas whilst overexpression of the protein occurs in
approximately 50% of cases (Barnes, 1997). Overexpression of
the cyclin D1 protein has also been demonstrated within the in situ
proliferations using immunohistochemistry with the percentage of
positive lesions and/or percentage of cyclin D1 positive cells
increasing with increasing cytological atypia (Alle et al, 1998;
Gillett et al, 1998; Mommers et al, 1998; Zhu et al, 1998). The
expression in cancers of cyclin D1 is strongly related to the
oestrogen receptor alpha (ER) status of the tumour. Oestrogens can
increase the level of cyclin D1 protein in early to mid G1, and thus
stimulate proliferation of cancer cell lines (Sutherland et al, 1995).
In the normal breast, however, there is a negative association
between expression of ER and the proliferation marker Ki67 indi-
cating that either ER-positive cells are non-dividing or that the
receptor is down-regulated as cells enter cycle. This important
relationship breaks down in many ER-positive cancers and precan-
cerous breast lesions where the receptor is often detected on prolif-
erating cells (Clarke et al, 1997; Shoker et al, 1999a, 2000).
Furthermore, it has been shown that D-type cyclins may intervene
in activities of transcription factors through mechanisms independ-
ent of cyclin-dependent kinases. Cyclin D1 can associate physic-
ally with the ER and stimulate its transcriptional functions in the
absence of oestrogen (Zwijsen et al, 1997). The relationship
between ER, cyclin D1 and proliferation in neoplastic and non-
neoplastic breast cells is thus not clear and it is possible that the
normal relationship breaks down during malignant transformation.
The aim of the present study was to determine the interplay
between ER, Ki67 and cyclin D1 within individual cells in the
spectrum of breast lesions ranging from normal to invasive car-
cinoma by using dual staining immunofluorescence. 
METHODS 
Patients 
Blocks and slides from 166 patients with breast disease were
obtained from the department of Pathology at the Royal Liverpool
University Hospital. The following breast lesions were examined in
these patients; 11 lactating breasts, 10 apocrine metaplasia, 9 scler-
osing adenosis, 15 radial scars, 11 papillomas, 10 fibroadenomas,
10 phyllodes tumours, 14 hyperplasias of usual type (without
atypia, HUT), 18 lobular in situ neoplasia (LIN), 8 atypical ductal
hyperplasias (ADH), 11 ductal carcinoma in situ (DCIS) of low
nuclear grade (LNG), 12 of intermediate nuclear grade (ING), 
11 of ER-negative high nuclear grade (HNG), 9 ER-positive HNG,
10 ER-negative infiltrating ductal carcinoma (IDC) and 10 ER-
positive IDC. Some of the breast samples examined contained 
more than one lesion. All the diagnoses were made following 
the Pathology Guidelines of the European and NHS Breast Screen-
ing Programmes (National Co-ordinating Group for Breast Screening
Pathology, 1997). The cases of ADH were from biopsies showing
benign changes only. The criteria for diagnosing ADH were those
of Page and Rogers (1992). Initially, the lobular in situ prolifer-
ations were subclassified into lobular carcinoma in situ and atypical
lobular hyperplasia but there were often significant difficulties in
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distinguishing the 2 processes which frequently merged in the
same sections. Furthermore, the results eventually obtained were
similar in the 2 lesions. The mean ages of the patients are given in
Table 1. The menopausal status or stage of menstrual cycle for
each patient was not known. 
Mitotic counting in breast cancers 
The number of mitoses within 10 high powered fields (hpf, mag-
nification ´ 400, field diameter 640 mm) was calculated for all the
invasive breast cancers. Mitotic figures were recognized according
to the criteria described by Baak and Oort (1983). In addition the
mitotic activity index (MAI) was calculated and expressed as the
number of mitoses per 1000 cells. These were then correlated with
the percentage of cyclin D1 and Ki67-positive cells within the
cancers. 
Dual immunofluorescence immunohistochemistry 
Dual immunofluorescent immunohistochemistry was performed
by combining a primary monoclonal mouse antibody with a
primary polyclonal rabbit antibody. The monoclonal antibodies
used were ER 1D5 (Dako, Cambridge, UK) and cyclin D1 (Dako)
and the polyclonal antibodies were Ki67 (Novacastra, Newcastle
upon Tyne, UK) and ER (Santa Cruz Biotechnology Inc, Santa
Cruz, California, USA). In order to verify that both ER antibodies
were staining the same cells, dual immunofluorescence was
performed with the 2 ER antibodies on normal breast tissue and on
invasive carcinomas. 
4 micrometer sections were cut onto 2% aminopropyltri-
ethoxysilane (APES)-coated slides and dried overnight at 45˚C.
The sections were dewaxed in 2 changes of xylene followed by 2
changes of industrial methylated spirits and then rinsed in deion-
ized water. Pretreatment comprised microwaving for 15 min at full
power in 10 mM EDTA (pH 7). A mixture of both primary anti-
bodies (diluted in 5% bovine serum albumin [BSA]/Tris buffered
saline [TBS]) was then applied for 80 min. The dilution used for
ER 1D5 was 1/30, for Ki67 1: 100, for cyclin D1 1:20 and for poly-
clonal ER 1:30. BSA/TBS was applied to all negative controls. A
mixture of both secondary antibodies, diluted in 5% BSA/TBS,
was then applied for 30 min. The secondary antibodies used were
TRITC-conjugated swine anti-rabbit antibody 1:50 (Dako) and
biotinylated sheep anti-mouse antibody 1:100 (Amersham Life
Sciences, UK). Next fluorescein-avidin conjugate (Dako) 1:100
(diluted in 5% BSA/TBS) was applied for 30 min. Washes in TBS
were performed between each step. Finally the slides were
immersed in a solution of 4¢, 6-diamidino-2-phenylindole (Sigma,
Poole, UK) at a concentration of 250 ng ml–1 in TBS for 10 min.
The slides were then coverslipped and mounted using an
antifading medium (Vectashield, Vector Laboratories, UK). 
Assessment of immunostaining 
Quantification of the fluorochrome-labelled cells was performed
by either scoring the entire lesion or approximately 1000 cells
across several representative fields (chosen using a 4¢,6-
diamidino-2-phenylindole filter). Each field was examined under a
high power lens for the red (TRITC), green (fluorescein) and blue
(4¢, 6-diamidino-2-phenylindole) fluorochromes using the appro-
priate filters in succession to assess the presence or absence
of double-labelled cells. A triple band filter in which all three
fluorochromes could be seen simultaneously was used for
confirmation of dual staining. If normal breast tissue was present
around the benign or malignant lesions studied then it was also
examined. 
Data analysis 
For all normal and pathological categories the percentage of cells
staining for each marker and for both were calculated. Also calcu-
lated were the percentage of double-labelled cells that would be
expected if the 2 variables were independent. This was calculated
by multiplying the percentage of cyclin D1 and Ki67-positive cells
or the percentage of cyclin D1 and ER-positive cells and then
dividing by 100 for each individual lesion. The actual number of
dual positive cells and the number expected were then compared
using the paired t-test. The observed/expected (O/E) ratio gives an
indication of whether, in any of the lesions studied, the 2 markers
were positively or negatively associated with each other and the
strength of the association. In the former, values of greater than 1
would be expected and in the latter, less than 1. The data were also
analysed by using Pearsons Product Moment Correlation
Coefficient (PPMCC) and the Mann–Whitney and Kruskal–Wallis
tests using SPSS software for Windows NT. 
RESULTS 
Comparison of monoclonal ER 1D5 and polyclonal ER
antibodies 
Dual staining for both ER antibodies was performed in 9 cases of
normal breast and 5 IDC (3 ER-positive). A perfect positive correl-
ation was achieved in both normal breast and IDC (PMCC 
r = 1.00, P < 0.0001). Of the 1920 ER-positive cells identified in
normal breast using the ER 1D5 antibody, more than 99% of the
cells were also positive with the polyclonal ER antibody. The
converse was also true. 
Cyclin D1, ER and Ki67 in normal breast 
In normal breast Ki67 positive cells represented approximately 3%
of the epithelial cell population whilst only 0.3% of cells contained
immunodetectable cyclin D1 (Table 1). Approximately 1300 Ki67-
positive cells were identified in normal breast, however, none coex-
pressed cyclin D1. The mean percentage of ER-positive cells in
normal breast was 20% (samples mainly from women in the peri-
menopausal age group) and in these specimens approximately half
of the cyclin D1-positive cells coexpressed ER (Table 2). The cyclin
D1-positive cells were more likely to express ER than the cyclin 
D1-negative cells (paired t-test for observed vs expected values 
P = 0.04) and were less likely to coexpress Ki67 (paired t-test for
observed vs expected values P< 0.0001). In addition, the percentage
of Ki67-positive cells decreased with increasing age (PPMCC, 
r = –0.427 P < 0.0001) whilst the percentage of cyclin D1–positive
cells increased with increasing age (PPMCC, r = 0.255 P = 0.02). 
Cyclin D1, ER and Ki67 in invasive cancer 
Invasive breast cancers had a high percentage of Ki67 positive cells
(Table 1), the percentage was significantly higher in 
ER-negative than ER-positive tumours (Mann–Whitney P = 0.01).
Cyclin D1-positive cells were found in 70% of ER-positive IDC andin 30% of ER-negative IDC. However, the number of cases that were
considered positive for cyclin D1 depended upon the cut-off point
used (Table 3). The mean percentage of cyclin D1-
positive cells was significantly higher than that seen in normal breast
tissue for ER-positive (Mann–Whitney P = 0.004) but not for ER-
negative (Mann–Whitney, P = 0.9) breast cancers. However, no cells
coexpressing cyclin D1 and Ki67 were seen in ER-negative IDC and
only in 2 cases (20%) of ER-positive IDC were cells coexpressing
cyclin D1 and Ki67 identified, although even in these cases the
majority of cyclin D1 cells did not coexpress Ki67. In contrast, there
was a strong positive correlation between the percentage of cyclin
D1-positive and ER-positive cells (PPMCC, r = 0.617, P = 0.0004). 
Mitoses and their relationship to Ki67 and cyclin D1 in
invasive cancer 
A mean of 2033 (SD 765) cells were counted for each case with a
mean MAI of 7.7. The median number of mitoses per 10 hpf
was 18. The MAI and the number of mitoses per 10 hpf showed
a strong correlation with the percentage of Ki67-positive
cells (PPMCC,  r = 0.669, P = 0.001 and r = 0.562, P = 0.01,
respectively). However, no significant correlation was found
between the MAI or the number of mitoses per 10 hpf and the
percentage of cells expressing cyclin D1 (PMCC r = –0.251, P =
0.3 and 
r = –0.252, P = 0.3, respectively). 
Cyclin D1 and Ki67 within proliferative breast disease 
Hyperplasia without atypia 
HUT had a significantly higher mean percentage of cyclin 
D1-positive cells than normal breast (Mann–Whitney, P= 0.03) and a
higher mean percentage of cells coexpressing Ki67 and cyclin D1
(Mann–Whitney, P< 0.0001) although the mean percentage of Ki67-
positive cells was similar (Mann–Whitney P = 0.23, Table 1).
However, HUT had a lower mean percentage of cyclin D1-positive
cells than ADH and DCIS LNG (Mann–Whitney, highest 
P = 0.009). HUT also had a lower mean percentage of Ki67-positive
cells than that seen in ADH and all grades of DCIS
(Mann–Whitney, highest P = 0.04). Of the 247 cyclin D1-
positive cells identified in all HUT only 4 cells coexpressed Ki67. 
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Table 1 The relationship between cyclin D1 and Ki67 in normal, benign and malignant breast lesions 
No of Mean Mean no. Mean percentage Mean percentage Mean percentage Mean percentage Mean
cases age (SD) cells cells cyclin D1 cells Ki67  cells dual  of dual positive observed/
counted positive (SD) positive (SD) positive (SD) cells expected  expected
(SD) (SD) (SD)
Normal breast 81 48 (14) 857 (311) 0.30 (0.50) 3.2 (4.7) 0.00 (0.0) 0.01 (0.02) 0.0 (0.0) 
Lactating breast 11 31 (7) 978 (235) 0.03 (0.06) 2.6 (2.2) 0.02 (0.06) 0.002 (0.004) 6.65 (9.4) 
Apocrine metaplasia 10 55 (11) 819 (275) 2.7 (6.0) 2.6 (2.2) 0.10 (0.33) 0.13 (0.30) 0.27 (0.54) 
Sclerosing adenosis 9 51 (13) 846 (311) 1.7 (2.9) 2.8 (2.9) 0.03 (0.09) 0.10 (0.19) 0.24 (0.59) 
Radial scar 15 57 (9) 1509 (513) 0.72 (1.0) 2.0 (2.2) 0.01 (0.05) 0.02 (0.04) 0.19 (0.54) 
Papilloma 11 53 (12) 1166 (109) 4.4 (4.6) 6.3 (3.6) 0.10 (0.14) 0.30 (0.40) 0.28 (0.41) 
Fibroadenoma 10 37 (11) 1063 (51) 7.7 (7.6) 9.5 (7.5) 0.34 (0.51) 0.98 (1.3) 0.18 (0.20) 
Phyllodes tumour 10 53 (14) 1090 (65) 2.6 (3.2) 5.1 (4.0) 0.03 (0.06) 0.11 (0.14) 0.14 (0.21) 
Hyperplasia without atypia 14 53 (13) 686 (414) 2.7 (3.7) 3.5 (3.6) 0.03 (0.06) 0.10 (0.15) 0.31 (0.50) 
Atypical ductal hyperplasia 8 50 (9) 829 (347) 17 (21) 6.0 (1.9) 0.46 (0.97) 1.15 (1.36) 0.16 (0.29) 
Lobular in situ neoplasia 18 54 (8) 791 (414) 8.4 (13) 2.7 (2.6) 0.14 (0.26) 0.32 (0.64) 0.63 (1.0) 
DCIS Low nuclear grade 11 63 (11) 1144 (152) 15 (14) 8.3 (6.3) 0.33 (0.67) 1.5 (2.0) 0.13 (0.16) 
DCIS Intermediate 
nuclear grade 12 54 (9) 1115 (157) 12 (18) 11 (10) 0.72 (1.8) 1.9 (4.9) 0.27 (0.40) 
DCIS High nuclear grade 
(ER negative) 10 56 (13) 866 (295) 3.6 (4.9) 15 (7.0) 0.12 (0.19) 0.60 (0.96) 0.36 (0.51) 
DCIS High nuclear grade 
(ER positive) 9 58 (6) 921 (194) 14 (17) 19 (15) 0.41 (0.51) 2.4 (3.0) 0.21 (0.40) 
Invasive ductal carcinoma 
(ER negative) 10 59 (12) 1187 (109) 1.4 (3.5) 44 (30) 0.00 (0.00) 0.26 (0.54) 0.00 (0.00) 
Invasive ductal carcinoma 
(ER positive) 10 54 (12) 1170 (164) 10 (16) 16 (13) 0.25 (0.55) 1.6 (2.6) 0.07 (0.13) 
Table 2 The relationship between cyclin D1 and ER in normal breast and invasive carcinoma 
No. of Mean Mean No. Mean percentage Mean percentage Mean percentage Mean percentage Mean
cases age (SD) cells cells cyclin D1 cells ER  cells dual  of dual positive observed/
counted positive (SD) positive (SD) positive (SD) cells expected  expected
(SD) (SD) (SD)
Normal breast 16 52 (16) 760 (278) 0.61 (0.65) 20 (21) 0.36 (0.61) 0.15 (0.29) 2.2 (2.0) 
Infiltrating ductal 
carcinoma ER+ 10 54 (12) 1088 (86) 12 (16) 65 (23) 11 (15) 9.5 (13) 1.0 (0.60) 
Infiltrating ductal 
carcinoma ER– 10 59 (12) 1075 (185) 1.1 (3.2) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) – Cyclin D1 and proliferation in breast 1067
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Atypical hyperplasia and in situ neoplasia 
The mean percentage of both cyclin D1-positive and Ki67-positive
cells within ADH and LNG DCIS were similar and were higher
than that seen in normal breast (Mann–Whitney, highest 
P = 0.002) but similar to that seen in ING DCIS and ER-positive
HNG DCIS. However, ER-negative HNG DCIS, when compared
with ADH and LNG DCIS, had a lower value for the mean percentage
of cyclin D1-positive cells (Mann–Whitney, highest P = 0.01) and
a higher value for the mean percentage Ki67-positive cells (Mann
Whitney, highest P = 0.04, Table 1). Only 3 cases of ADH
contained any cells coexpressing cyclin D1 and Ki67, representing
13 cells of a total of 885 cyclin D1-positive cells counted. LIN had
a higher mean percentage of cyclin D1-positive cells than normal
breast but showed no difference when compared with HUT, ADH
and DCIS (all nuclear grades). The mean percentage of Ki67-
positive cells was similar to that seen in normal breast and HUT
but was lower than that seen in ADH or DCIS (all nuclear grades).
Cells coexpressing cyclin D1 and Ki67 were infrequently identi-
fied in all these lesions (Table 1, Table 3). 
Other benign breast lesions 
The other benign breast lesions associated with an increased risk
of 1.5–2.0 of subsequently developing breast cancer e.g. scler-
osing adenosis, radial scar, papilloma and fibroadenoma, had a
wide range of values for the mean percentage of cyclin D1- and
Ki67-positive cells (Table 1). Some of the lesions had values
similar to normal breast, others similar to HUT and yet still others
with values similar to ADH. However, in all breast lesions studied,
cells coexpressing cyclin D1 and Ki67 were either not present or
only present very infrequently (Table 1, Table 3). The mean
observed /expected value for all lesions, except lactating breast,
was below 1 (Figure 1). The high observed/expected ratio noted in
lactating breast was because only 3 cyclin D1-positive cells were
identified of which 2 coexpressed Ki67. 
DISCUSSION 
Cyclin D1 is known to be important in cell cycle control by regu-
lating progression through the G1 phase of the cell cycle
(Sutherland et al, 1995). Ki67 is a marker of proliferation and in
the present study correlated strongly with the mitotic count and the
MAI. Ki67 has also been shown to correlate with radioactive
Table 3 Cyclin D1 positivity in breast lesions using different cut off points and their relationship to cases that contain cells coexpressing ER and Ki67 
No. of cases Cases with >1% cyclin  Cases with >5% cyclin  Cases with >10% cyclin  Cases containing
D1 positive cells D1 positive cells D1 positive cells cyclin D1+ /Ki67+
(percentage) (percentage) (percentage) cells (percentage)
Normal breast 81 6 (7.4) 0 (0) 0 (0) 0 (0) 
Lactating breast 11 0 (0) 0 (0) 0 (0) 1 (9) 
Apocrine metaplasia 10 3 (30) 1 (10) 1 (10) 1 (10) 
Sclerosing adenosis 9 3 (33) 1 (11) 0 (0) 1 (11) 
Radial scar 15 5 (33) 0 (0) 0 (0) 1 (7) 
Papilloma 11 9 (82) 3 (27) 3 (27) 5 (45) 
Fibroadenoma 10 8 (80) 5 (50) 4 (40) 5 (50) 
Phyllodes tumour 10 5 (50) 1 (10) 0 (0) 2 (20) 
Hyperplasia without atypia 14 6 (43) 3 (21) 0 (0) 2 (14) 
Atypical ductal hyperplasia 8 7 (87) 5 (62) 5 (62) 3 (37) 
Lobular in situ neoplasia 18 10 (56) 8 (44) 5 (28) 7 (39) 
DCIS Low nuclear grade 11 9 (82) 8 (73) 7 (64) 6 (55) 
DCIS Intermediate nuclear grade 12 8 (67) 6 (50) 4 (33) 4 (33) 
DCIS High nuclear grade 
(ER negative) 11 4 (36) 4 (36) 2 (18) 4 (36) 
DCIS High nuclear grade 
(ER positive) 9 7 (78) 4 (44) 4 (44) 5 (56) 
Invasive ductal carcinoma 
(ER negative) 10 2 (20) 1 (10) 1 (10) 0 (0) 
Invasive ductal carcinoma 
(ER positive) 10 5 (50) 4 (40) 3 (30) 2 (20) 
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Figure 1 Boxplot graph of the observed/expected percentage of cells
coexpressing cyclin D1 and Ki67 in normal breast, benign breast lesions and
invasive breast carcinoma. Boxplot graphs in which the line across the box
indicates the median, the box contains the values between the 25th and 75th
percentiles, the whiskers extend to the highest and lowest values excluding
outliers, ˚
and * identifies outliers and extreme values (Norm, normal breast;
AM, apocrine metaplasia; HUT, hyperplasia of usual type (without atypia);
SA, sclerosing adenosis; RS, radial scar; PAP, papilloma, FA, fibroadenoma;
PT, phyllodes tumour; ADH, atypical ductal hyperplasia; LNG, low nuclear
grade ductal carcinoma in situ (DCIS); ING, intermediate nuclear grade
DCIS; HNG, high nuclear grade DCIS, ER–, oestrogen receptor negative,
ER+, oestrogen receptor positive; IDC, infiltrating ductal carcinoma; LIN,
lobular in situ neoplasia) 1068 BS Shoker et al 
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thymidine labelling when used as a cell cycle marker (Clarke et al,
1997). However, interestingly we did not see any Ki67-positive
cells coexpressing cyclin D1 in normal breast despite looking at
over 1300 Ki67-positive cells. In breast cancer cyclin D1 overex-
pression by immunohistochemistry is associated with low-grade
ER-positive breast cancers that have a low proliferation rate (van
Diest et al, 1997). In our study, in ER-negative breast cancers that
contained a high percentage of Ki67-positive cells few or no cyclin
D1-positive cells were detected. Cyclin D1-positive cells that were
present did not coexpress Ki67. De Jong et al (1999) used dual
staining immunofluorescence for cyclin D1 and Ki67 on 6 cancers,
3 of which were from the breast. Coexpression of cyclin D1 and
Ki67 was not seen in the breast cancers but 2 squamous cell carcin-
omas from the head and neck region contained occasional dual-
labelled cells in the basal layers. Although co-expression of cyclin
D1 and Ki67 is occasionally seen within the in situ proliferations,
cyclin D1-positive cells generally are less likely to be dividing than
the cyclin D1-negative cells. Hence in the majority of cases, it
would appear that cyclin D1 expression is not associated with cell
cycle progression. 
In normal breast we found that cyclin D1 and ER were
positively associated. Furthermore, the percentage of cyclin D1-
positive cells increased with age, a similar effect was seen for ER in
normal breast (Shoker et al, 1999b). This supports the finding that
cyclin D1 is an ER-regulated gene (Sutherland et al, 1995),
possibly being more likely to be switched on in environments in
which low serum oestrogen concentrations prevail allowing cells
to differentiate along an ER-positive pathway. Cyclin D1-positive
cells were also more likely to be present within ER-positive than
ER-negative DCIS and invasive cancer. The disparity between the
amplification of the cyclin D1 gene and the overexpression of
cyclin D1 protein in breast cancers (Barnes, 1997) may therefore
be due to the dysregulation of ER that occurs in the majority of
these lesions (Shoker et al, 1999a, 1999b, 2000). The mutual
expression of cyclin D1 and ER could allow the direct stimulation
of ER pathways in the absence of oestrogen and may have an
important role in the aetiology of ER positive cancers (Zwijsen 
et al, 1997). 
The overexpression of the cyclin D1 gene has been associated
with high telomerase activity without an increase in tumour cell
proliferation (Landberg et al 1997). In a mammary epithelial cell
line, transduction of cyclin D1 inhibited growth, possibly due to
prolongation of the S-phase (Han et al, 1995). Similarly, expres-
sion of ER in previously ER-negative cell lines leads to growth
inhibition (Zajchowski et al, 1993). The prevention of ER or cyclin
D1-expressing cells to enter division is possibly achieved by the
action of cyclin-dependent kinase inhibitors, e.g. p21Cip1 and
p27Kip1, which have been described as markers of differentiation in
breast epithelia. Cells overexpressing cyclin D1 also frequently
coexpress p21Cip1 (de Jong et al, 1999) and, in grade I breast
cancers, p27Kip1 expression is correlated with both ER and cyclin
D1 (Leong et al, 2000). Whilst both ER and cyclin D1 play an
important role in cellular proliferation and in tumorigenesis, their
action would seem to favour differentiation and thus lead to an
association with less aggressive breast tumours. The expression of
cyclin D1 may therefore be important in both proliferation and
differentiation, the pathway followed depending upon other cell
cycle regulators that are also present within the cell. 
Overexpression of the cyclin D1 protein is common in breast
cancer (Barnes, 1997). In transgenic mice, when the cyclin D1
gene is linked to the mouse mammary tumour virus promoter, the
mice develop precancerous hyperplasias and only after long latent
periods do they develop carcinomas (Wang et al, 1994). Thus a
number of studies have looked at precancerous breast lesions to
see whether this represents an early change in the progression to
neoplasia. One of the first studies looked at cyclin D1 mRNA
expression using in situ hybridization. It found overexpression in
18% of benign breast lesions and ADH and in 76% of LNG DCIS,
87% HNG DCIS and 83% IDC and suggested that cyclin D1 may
be useful in separating benign and premalignant breast lesions
from any form of breast carcinoma (Weinstat-Saslow et al, 1995).
Gillett et al (1998) looked at protein overexpression by immuno-
histochemistry and found that it was present in 64% of cases of
DCIS and in only 14% of cases of ADH although a further 7 of 9
cases did show weak staining. A number of other studies have
found a graded increase in cyclin D1 overexpression from normal
to HUT to ADH to DCIS and finally to invasive cancer with
significant differences not always being seen between the lesions
(Alle et al, 1998; Mommers et al, 1998; Zhu et al, 1998). Our own
findings agree with these latter studies. The mean percentage of
cyclin D1-positive cells is higher within the in situ proliferations
than in normal breast. ADH had values higher than those seen for
HUT but similar to those seen in ER-positive DCIS. The
percentage of cyclin D1-positive cells in these lesions thus seems
to correlate with the percentage of ER-positive cells also found in
these lesions (Shoker et al, 1999a, 1999b, 2000). However, the
other low-risk breast lesions contain a variable percentage of
cyclin D1-positive cells, some lesions have similar values to HUT
whilst other have higher values that approach the atypical prolifer-
ations. The usefulness of cyclin D1 in separating benign from
malignant lesions is therefore not clear cut. 
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